叶酸及维生素B12水平对培美曲塞联合铂类化疗的维汉两族NSCLC患者疗效的影响

目的 探讨叶酸及维生素B12水平对一线使用培美曲塞联合铂类化疗的维吾尔族(以下简称维族)和汉族非小细胞肺癌(NSCLC)患者疗效的影响.方法 取一线使用培美曲塞联合铂类化疗方案并至少完成2个周期本方案化疗初治的维族及汉族NSCLC患者共61例.采用电化学发光法在治疗前检测患者的叶酸和维生素B12水平,并至少每2个周期进行化疗疗效评价1次,随访至患者出现疾病进展或一线化疗完成,并对两民族患者间收集的数据进行比较分析.结果 维汉两族NSCLC患者的性别、吸烟史、年龄、肿瘤分化程度、肿瘤分期、血清维生素B12水平比较,差异无统计学意义(P＞0.05);但汉族NSCLC患者血清叶酸水平较维族患者高(P＜0.05).性别、吸烟史、年龄、肿瘤分化程度、肿瘤分期、血清维生素B12水平均对使用培美曲塞联合铂类化疗的NSCLC患者预后无影响(P＞0.05),而汉族患者较维族患者预后好(P＜0.05),血清叶酸水平较高的患者预后好(P＜0.05).汉族NSCLC患者的无进展生存期(PFS)明显优于维族NSCLC患者.结论 汉族NSCLC患者血清叶酸水平较维族高,接受培美曲塞联合铂类化疗的疗效明显优于维族,血清叶酸水平可能与NSCLC患者预后相关.

Influence of folic acid and vitamin B12 levels on curative effect in Uygur and Han patients with non-small ceil lung cancer treated by pemetrexed combine with platinum chemotherapy

Objective To investigate the influence of folic acid and vitamin B12 levels on the curative effect in Uygur and Han patients with non-small cell lung cancer(NSCLC) treated by first-line chemotherapy of pemetrexed combine with platinum.Methods Sixty-one Uygur and Han cases of NSCLC treated by the first-line chemotherapy of pemetrexed combine with platinum and at least two cycles of this regimen were selected.The folic acid and vitamin B12 levels before chemotherapy were detected by using the electrochemiluminescence method.The chemotherapeutic effect evaluation was performed once at least per 2 weeks.The follow up lasted until the disease progress or first line chemotherapy finish,furthermore the data collected from the two nationalities were performed the comparative analysis.Results The gender,smoking history,age,differentiation degree,staging and vitamin B12 level had no statistical differences between Uygur and Han NSCLC patients(P＞0.05);but the serum folic acid level in Han NSCLC patients was higher than that in Uygur NSCLC patients(P＜0.05).The gender,smoking history,age,tumor differentiation degree,neoplasm staging and serum vitamin B12 level had no influence on the prognosis in NSCLC patients using the pemetrexed combine with platinum chemotherapy(P＞0.05),while the prognosis in Han patients was better than that in Uygur patients(P＜0.05),and the patients with higher folic acid level had good prognosis.The progress free survival(PFS) in Han NSCLC patients was obviously superior to that in Uygur patients.Conclusion The serum folic acid level in Han NSCLC patients is higher than that in Uygur patients,and the curative effect in Han patients receiving the pemetrexed combine with platinum chemotherapy is obviously superior to that in Uygur patients,and serum folic acid level may be related with the prognosis in NSCLC patients.